These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36264322)

  • 1. [Evidence-based health care with pharmaceuticals for rare diseases: the role of digitalisation].
    Naumann-Winter F; Kaiser T; Behring A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Nov; 65(11):1170-1177. PubMed ID: 36264322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders.
    Parker S
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv9-14. PubMed ID: 25165190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
    McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
    Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.
    Kusch M; Labouvie H; Schiewer V; Talalaev N; Cwik JC; Bussmann S; Vaganian L; Gerlach AL; Dresen A; Cecon N; Salm S; Krieger T; Pfaff H; Lemmen C; Derendorf L; Stock S; Samel C; Hagemeier A; Hellmich M; Leicher B; Hültenschmidt G; Swoboda J; Haas P; Arning A; Göttel A; Schwickerath K; Graeven U; Houwaart S; Kerek-Bodden H; Krebs S; Muth C; Hecker C; Reiser M; Mauch C; Benner J; Schmidt G; Karlowsky C; Vimalanandan G; Matyschik L; Galonska L; Francke A; Osborne K; Nestle U; Bäumer M; Schmitz K; Wolf J; Hallek M
    BMC Health Serv Res; 2022 Apr; 22(1):543. PubMed ID: 35459202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Access to medicines for rare diseases: regulatory aspects and public health priorities.].
    Costa E; Grimaldi G; Del Grosso V; Isgrò A; Genazzani A
    Recenti Prog Med; 2022; 113(7):415-424. PubMed ID: 35852076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registries for orphan drugs: generating evidence or marketing tools?
    Hollak CEM; Sirrs S; van den Berg S; van der Wel V; Langeveld M; Dekker H; Lachmann R; de Visser SJ
    Orphanet J Rare Dis; 2020 Sep; 15(1):235. PubMed ID: 32883346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders.
    Jonker CJ; de Vries ST; van den Berg HM; McGettigan P; Hoes AW; Mol PGM
    Drug Saf; 2021 Aug; 44(8):853-861. PubMed ID: 34091881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The medical informatics initiative and rare diseases: next-generation routine data for diagnosis, therapy selection and research].
    Schepers J; Fleck J; Schaaf J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Nov; 65(11):1151-1158. PubMed ID: 36305897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
    Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
    JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.